Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: Two infants treated with sebelipase alfa
- PMID: 29705274
- DOI: 10.1016/j.clinre.2018.03.012
Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: Two infants treated with sebelipase alfa
Abstract
Two unrelated infants were diagnosed with and initially treated for hemophagocytic lymphohistiocytosis (HLH), but progressed to cholestasis and liver failure. Early onset lysosomal acid lipase deficiency (EO-LAL-D) was suspected due to lymphocytes with cytoplasmic vacuolation and/or adrenal calcifications and confirmed by enzymatic and genetic analysis. Enzyme replacement therapy with sebelipase alfa was implemented, but both children died, despite initial improvement. Since this inborn error of metabolism progresses rapidly in infants, early diagnosis is crucial, and appropriate treatment should be started as soon as possible. The authors suggest that the diagnosis of EO-LAL-D should be considered in infants with symptoms of HLH.
Keywords: Early onset lysosomal acid lipase deficiency; Hemophagocytic lymphohistiocytosis; Hepatosplenomegaly; Neonatal cholestasis; Sebelipase alfa; Wolman disease.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.Orphanet J Rare Dis. 2017 Feb 8;12(1):25. doi: 10.1186/s13023-017-0587-3. Orphanet J Rare Dis. 2017. PMID: 28179030 Free PMC article. Clinical Trial.
-
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies.Orphanet J Rare Dis. 2021 Jan 6;16(1):13. doi: 10.1186/s13023-020-01577-4. Orphanet J Rare Dis. 2021. PMID: 33407676 Free PMC article.
-
Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency.Drugs Today (Barc). 2016 May;52(5):287-93. doi: 10.1358/dot.2016.52.5.2488974. Drugs Today (Barc). 2016. PMID: 27376161 Review.
-
Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency.Am J Cardiovasc Drugs. 2016 Dec;16(6):461-468. doi: 10.1007/s40256-016-0203-2. Am J Cardiovasc Drugs. 2016. PMID: 27878737 Review.
-
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency.J Clin Lipidol. 2018 May-Jun;12(3):604-614. doi: 10.1016/j.jacl.2018.02.020. Epub 2018 Mar 9. J Clin Lipidol. 2018. PMID: 29628368 Clinical Trial.
Cited by
-
Lysosomal Acid Lipase Deficiency: A Report of Two Cases and a Review of the Literature.Cureus. 2024 Nov 8;16(11):e73299. doi: 10.7759/cureus.73299. eCollection 2024 Nov. Cureus. 2024. PMID: 39650963 Free PMC article.
-
The Liver and Lysosomal Storage Diseases: From Pathophysiology to Clinical Presentation, Diagnostics, and Treatment.Diagnostics (Basel). 2024 Jun 19;14(12):1299. doi: 10.3390/diagnostics14121299. Diagnostics (Basel). 2024. PMID: 38928715 Free PMC article. Review.
-
Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms.Eur J Pediatr. 2019 Apr;178(4):515-523. doi: 10.1007/s00431-019-03328-5. Epub 2019 Jan 28. Eur J Pediatr. 2019. PMID: 30693370
-
Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease.Nutrients. 2024 Dec 13;16(24):4309. doi: 10.3390/nu16244309. Nutrients. 2024. PMID: 39770929 Free PMC article. Review.
-
Diagnosis, treatment, and follow-up of a case of Wolman disease with hemophagocytic lymphohistiocytosis.Mol Genet Metab Rep. 2021 Dec 20;30:100833. doi: 10.1016/j.ymgmr.2021.100833. eCollection 2022 Mar. Mol Genet Metab Rep. 2021. PMID: 35242567 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources